LENZ Therapeutics Inc (LENZ)vsBeiGene, Ltd. (ONC)
LENZ
LENZ Therapeutics Inc
$9.03
-17.91%
HEALTHCARE · Cap: $344.19M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 30432% more annual revenue ($5.34B vs $17.50M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
LENZ
Avoid30
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LENZ.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LENZ
The strongest argument for LENZ centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : LENZ
The primary concerns for LENZ are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
LENZ profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
LENZ carries more volatility with a beta of 1.76 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 30/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LENZ Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
LENZ Therapeutics Inc is an innovative biopharmaceutical company dedicated to developing breakthrough therapies for neurological disorders, addressing significant unmet medical needs in the central nervous system (CNS). Utilizing advanced research in drug formulation and delivery, LENZ aims to enhance patient outcomes through its proprietary technologies and a robust product pipeline. The company’s strategic partnerships and commitment to rigorous clinical research underscore its potential as a key player in the biopharmaceutical industry, positioning it for considerable growth and influence in the evolving healthcare landscape.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?